H. Lundbeck, Bifeprunox; Update on registration plans in Europe

H. Lundbeck A/S announced today that the ongoing review of bifeprunox clinical data leads to a delayed submission of a registration dossiers in the EU, now aimed for 2008, depending on the completion of additional phase III comparative clinical work.